Purpose: To assess the influence of perfusion on apparent coefficient diffusion (ADC) maps, the contribution of b-value images, and the number of b-values needed in prostate cancer detection by diffusion-weighted imaging (DWI).
Materials And Methods: Patients scheduled for prostatectomy were scanned by 3T magnetic resonance imaging (MRI) with DWI based on b-values 0-500-1000-1500 s/mm(2) . A monoexponential model was fitted to obtain ADC using multiple b-values, with or without b0 (perfusion-sensitive ADC4b-b0-500-1000-1500 , perfusion-insensitive ADC3b-b500-1000-1500 ), or two b-values (ADC2b-b0-500 , ADC2b-b0-1000 , ADC2b-b0-1500 ). Prostate and cancer foci were segmented to label voxels as normal or tumoral, according to histology. Areas under receiver operating characteristic curves (AUC) were calculated for each ADC and b-value, then for multivariate logistic regression models combining them. A threshold of 85 tumoral voxels (=0.5 cm(3) ) was used to stratify AUC analysis.
Results: In all, 21 patients were selected. Segmentation collected 143,665 prostatic voxels including 10,069 tumoral voxels. In five patients, tumor segmentation provided fewer than 85 voxels, resulting in an ADC with AUC inferior to 0.52. In 16 patients with larger tumors, perfusion-sensitive ADC4b-b0-500-1000-1500 performed better than perfusion-insensitive ADC3b-b500-1000-1500 and similar to ADC2b-b0-1500 (AUC of 0.840, 0.809, and 0.838, respectively). In comparison to the ADC alone, models combining ADC4b-b0-500-1000-1500 or ADC2b-b0-1500 with b1500 improved performance, leading to similar AUCs of 0.884 and 0.883, respectively. In both models, ADC and b1500 were significant markers (P < 0.001).
Conclusion: Including b0 in ADC calculation provided superior ADC maps for prostate cancer detection. b1500 images as a combined parameter with ADC also improved performance. Using more than two b-values showed no improvement. J. Magn. Reson. Imaging 2016;44:601-609.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmri.25206 | DOI Listing |
Cancer Res Commun
January 2025
University of Minnesota, Minnesota, MN, United States.
Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Department of Biotechnology, Kakatiya University, Warangal, Telangana, India.
Objective: A new library of Thiazolidine-2,4-dione-biphenyl Derivatives derivatives (10a-j) was designed and synthesized. All compounds were characterized by spectral data. Further, these were evaluated for their in vitro anticancer activity.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Postgraduate Program in Oncology, Haroldo Juaçaba Hospital, Ceará Cancer Institute (ICC), Brazil.
Objective: This study aimed to investigate the influence of p16 immunohistochemical expression on the biochemical recurrence rate of pT2-pT3 prostate cancer.
Materials And Methods: A total of 488 pT2-pT3 stage prostate adenocarcinomas undergoing radical prostatectomy were included in this study. Following a review of Gleason classification and retrieval of sociodemographic and clinicopathological data, as well as the date of last consultation and biochemical recurrence, immunohistochemistry for p16 was performed.
FASEB J
January 2025
Prostate Cancer/Genitourologic Program, Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Among the known nuclear exportins, CRM1 is the most studied prototype. Dysregulation of CRM1 occurs in many cancers, hence, understanding the role of CRM1 in cancer can help in developing synergistic therapeutics. The study investigates how CRM1 affects prostate cancer growth and survival.
View Article and Find Full Text PDFBr J Radiol
January 2025
Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical incications of the available agents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!